i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced investments in Ogwen Therapeutics, Llydaw Therapeutics and Mwyngil Therapeutics. The new companies, all members of the Loch platform established and supported by i2020 & OrbiMed Advisors, are developing novel targeted treatments for cancer, immunological and neurodegenerative diseases. With the financing, the partners continue to build a robust innovative asset pipeline focused on breakthrough drug targets. This brings the total funding for the Loch platform to over $90 million.
The Loch platform and its programs are supported by the AI and computer aided drug design of Molsoft LLC and ChemDiv Inc., San Diego, CA, as well as other research partners from i2020 Accelerator's global network.
About OrbiMed
OrbiMed has been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 100 distinguished scientific, medical, investment and other professionals manages over $19 billion across public and private company investments worldwide. From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives.
About i2020 Accelerator
i2020 Accelerator strives to accelerate early-stage drug discovery platforms towards advanced lead and clinical candidates within a two-year framework to rapidly de-risk novel science and enrich partner pipelines with first or best-in-class molecules. i2020's scientific and global resources network tailored specifically to the needs of early programs allows to accelerate development in multiple high value therapeutic areas, from immunology to inflammation and from oncology and CNS to infectious diseases and beyond. The i2020 accelerator program inaugurated by Torrey Pines Investment in 2017 is now co-creating, growing and graduating breakthrough drug discovery programs towards future medicines.